Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomesMathias Jachs, Thomas Reiberger, Christopher Desbalmes et al.|Gut|2020Cited by 98
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver diseaseLukas Hartl, Michael Trauner, Mattias Mandorfer et al.|Hepatology|2022Cited by 74
Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and DeathMathias Jachs, Mattias Mandorfer, David Bauer et al.|Clinical Gastroenterology and Hepatology|2021Cited by 56